|
1
|
Schweitzer A, Horn J, Mikolajczyk RT,
Krause G and Ott JJ: Estimations of worldwide prevalence of chronic
hepatitis B virus infection: A systematic review of data published
between 1965 and 2013. Lancet. 386:1546–1555. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ott JJ, Stevens GA, Groeger J and Wiersma
ST: Global epidemiology of hepatitis B virus infection: New
estimates of age-specific HBsAg seroprevalence and endemicity.
Vaccine. 30:2212–2219. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
European Association for the Study of the
Liver. Electronic address: simpleeasloffice@easloffice.eu;
European Association for the Study of the Live. EASL 2017 Clinical
Practice Guidelines on the management of hepatitis B virus
infection. J Hepatol. 67:370–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Baldick CJ, Eggers BJ, Fang J, Levine SM,
Pokornowski KA, Rose RE, Yu CF, Tenney DJ and Colonno RJ: Hepatitis
B virus quasispecies susceptibility to entecavir confirms the
relationship between genotypic resistance and patient virologic
response. J Hepatol. 48:895–902. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Doğan ÜB, Öztürk AB, Akın MS, Yalaki S and
Sayan M: A case of entecavir resistance which is developed after
complete viral suppression during entecavir treatment for
nucleoside-naïve chronic hepatitis B. Turk J Gastroenterol. 25
(Suppl 1):S206–S209. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lok ASF and McMahon BJ: Chronic hepatitis
B: Update 2009. Hepatology. 50:661–662. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bartholomeusz A and Locarnini SA:
Antiviral drug resistance: Clinical consequences and molecular
aspects. Semin Liver Dis. 26:162–170. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zoulim F: Hepatitis B virus resistance to
entecavir in nucleotide naïve patients: Does it exist? Hepatology.
44:1404–1407. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Colonno RJ, Rose R, Baldick CJ, Levine S,
Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, et al:
Entecavir resistance is rare in nucleoside naïve patients with
hepatitis B. Hepatology. 44:1656–1665. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tenney DJ, Rose RE, Baldick CJ,
Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J,
Wilber RB and Colonno RJ: Long-term monitoring shows hepatitis B
virus resistance to entecavir in nucleoside-naïve patients is rare
through 5 years-of therapy. Hepatology. 49:1503–1514.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Suzuki F, Akuta N, Suzuki Y, Yatsuji H,
Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, et
al: Selection of a virus strain resistant to entecavir in a
nucleoside-naïve patient with hepatitis B of genotype H. J Clin
Virol. 39:149–152. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lee HW, Kim HJ, Hong SP, Cha BK, Chang HY,
Choi CH, Do JH, Kim JG and Chang SK: Simultaneous emergence of
entecavir resistance mutations in a nucleoside-naïve chronic
hepatitis B patient. Intervirology. 55:380–384. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kobashi H, Fujioka S, Kawaguchi M, Kumada
H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H,
et al: Two cases of development of entecavir resistance during
entecavir treatment for nucleoside-naïve chronic hepatitis B.
Hepatol Int. 3:403–410. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gherlan GS: Liver ultrasound elastography:
More than staging the disease. World J Hepatol. 7:1595–1600.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cho WH, Lee HJ, Bang KB, Kim SB and Song
IH: Development of tenofovir disoproxil fumarate resistance after
complete viral suppression in a patient with treatment-naïve
chronic hepatitis B: A case report and review of the literature.
World J Gastroenterol. 24:1919–1924. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hulgan T and Haas DW: Toward a
pharmacogenetic understanding of nucleotide and nucleoside analogue
toxicity. J Infect Dis. 194:1471–1474. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Liu Y, Corsa AC, Buti M, Cathcart AL,
Flaherty JF, Miller MD, Kitrinos KM, Marcellin P and Gane EJ: No
detectable resistance to tenofovir disoproxil fumarate in HBeAg+
and HBeAg-patients with chronic hepatitis B after 8 years of
treatment. J Viral Hepat. 24:68–74. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lai CL, Chien RN, Leung NWY, Chang TT,
Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, et al: A one-year
trial of lamivudine for chronic hepatitis B. Asia Hepatitis
Lamivudine Study Group. N Engl J Med. 339:61–68. 1998.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kobayashi S, Ide T and Sata M: Detection
of YMDD motif mutations in some lamivudine-untreated asymptomatic
hepatitis B virus carriers. J Hepatol. 34:584–586. 2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lee CZ, Lee HS, Huang GT, Yang PM and Sheu
JC: Detection of YMDD mutation using mutant-specific primers in
chronic hepatitis B patients before and after lamivudine treatment.
World J Gastroenterol. 12:5301–5355. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tunçbilek S, Köse Ş, Elaldi A and Akman S:
Lamivudine resistance in untreated chronic hepatitis B patients in
Turkey. Turkish J Gastroenterol. 19:99–103. 2008.PubMed/NCBI
|
|
22
|
Huang CJ, Wu CF, Lan CY, Sung FY, Lin CL,
Liu CJ, Liu HF and Yu MW: Impact of Genetic Heterogeneity in
Polymerase of Hepatitis B virus on dynamics of viral load and
hepatitis B progression. PLoS One. 8(e70169)2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Choi YM, Lee SY and Kim BJ: Naturally
occurring hepatitis B virus reverse transcriptase mutations related
to potential antiviral drug resistance and liver disease
progression. World J Gastroenterol. 24:1708–1724. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang
J, An Y and Wang L: Incidence of natural resistance mutations in
naïve chronic hepatitis B patients: A systematic review and
meta-analysis. J Gastroenterol Hepatol. 30:252–261. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kim JE, Lee SY, Kim H, Kim KJ, Choe WH and
Kim BJ: Naturally occurring mutations in the reverse transcriptase
region of hepatitis B virus polymerase from treatment-naïve Korean
patients infected with genotype C2. World J Gastroenterol.
23:4222–4232. 2017.PubMed/NCBI View Article : Google Scholar
|
